Empagliflozin in patients with chronic kidney disease

Empagliflozin in patients with chronic kidney disease

<p><strong>Background</strong></p> The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range o...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Herrington, WG, Staplin, N, Green, JB, Hauske, SJ, Emberson, J, Preiss, D, Judge, P, Mayne, K, Ng, S, Sammons, E, Zhu, D, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Wen Liu, Kadowaki, T, Nangaku, M, Levin, A, Cherney, D, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Petrini, M, Massey, D, Eilbracht, J, Brueckmann, M, Landray, M, Baigent, C, Haynes, R
Muut tekijät: EMPA-KIDNEY Collaborative Group
Aineistotyyppi: Journal article
Kieli:English
Julkaistu: Massachusetts Medical Society 2022

Samankaltaisia teoksia